NeuroBo Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm committed to advancing treatments for a spectrum of challenging conditions, encompassing neurodegenerative disorders, infectious diseases, and cardiometabolic ailments. The company's diverse pipeline includes several investigational therapies: ANA001, an orally administered formulation of niclosamide, is currently progressing through Phase 2/3 clinical trials to treat individuals with moderate coronavirus disease (COVID-19). NB-01 is being developed to alleviate the discomfort associated with painful diabetic neuropathy. NB-02 targets the management of cognitive decline symptoms and seeks to alter the course of neurodegenerative conditions specifically linked to the malfunction of tau protein. Gemcabene is also part of their portfolio, under investigation for its potential in acute COVID-19 indications. NeuroBo Pharmaceuticals, Inc. maintains its corporate headquarters in Boston, Massachusetts.